An Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3866 When Administered to Subjects With Moderate and Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs MK-3866 (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 15 Jan 2019 Status changed to discontinue.
- 27 Mar 2018 Planned End Date changed from 30 Apr 2018 to 31 May 2018.
- 27 Mar 2018 Planned primary completion date changed from 30 Apr 2018 to 31 May 2018.